Website
News25/Ratings0
Price$1.59-0.51 (-24.41%)
2026-01-162026-04-22
News · 26 weeks28-100%
2025-10-262026-04-19
Mix1790d
- Insider6(35%)
- Other5(29%)
- SEC Filings3(18%)
- Earnings2(12%)
- Leadership1(6%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by SenesTech Inc.SCHEDULE 13G/A - SenesTech, Inc. (0001680378) (Subject)
- INSIDERLarge owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
- SECSenesTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SenesTech, Inc. (0001680378) (Filer)
- PRSenesTech Announces 2025 Financial Results Driven by Strong Growth in E-CommerceSURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re
- PRSenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa
- INSIDERLarge owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
- PRSenesTech Reports Significant Reductions in Rodent Activity Following Evolve® Deployments in Urban Field StudiesSURPRISE, Ariz., Feb. 18, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) ("SenesTech" or the "Company"), a leader in birth control solutions for managing rodent populations, today reported significant reductions in rodent activity following multi-month deployments of Evolve® Rat Birth Control in two urban locations. Results were measured using standardized tracking plate data conducted over a five-month period. Location A – Deployment Initiated April 2025In the first monitored area, where Evolve placement began in April 2025, tracking plate data collected from August 2025 th
- INSIDERLarge owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
- PRSenesTech Strengthens Direct-to-Consumer Commercial Strategy by Directly Managing Amazon Sales of Evolve™ Rat and Evolve™ MouseTransition from Third-Party to Internal Management Expected to Increase Revenue and Enhance Margin on E-Commerce Channel Moving Forward While Building on Early Success PHOENIX, Feb. 10, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) today announced that it will begin directly managing sales of its Evolve™ Rat and Evolve™ Mouse products on Amazon. The change reflects the Company's continued focus on e-commerce as an important distribution channel and will be effective immediately. In 2025, e-commerce represented over 50% of SenesTech's revenue, with about one half of that d
- INSIDERLarge owner Glenbrook Capital Management bought $15,480 worth of shares (8,569 units at $1.81) (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
- INSIDERLarge owner Glenbrook Capital Management bought $94,524 worth of shares (48,138 units at $1.96) (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SenesTech Inc.SCHEDULE 13G/A - SenesTech, Inc. (0001680378) (Subject)
- INSIDERNew insider Glenbrook Capital Management claimed ownership of 545,647 shares (SEC Form 3)3 - SenesTech, Inc. (0001680378) (Issuer)
- PRSenesTech's Evolve® Approved in New ZealandSupporting New Zealand's Predator Free 2050 Initiative Initial Stocking Order Fulfilled PHOENIX, Feb. 2, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, is pleased to announce that Evolve® has been approved for use in New Zealand by the Ministry for Primary Industries. SenesTech's exclusive distribution partner, Evicom, has been shipped its initial stocking order. Rodent overpopulation remains a major ecological and economic challenge in New Zealand, threatening native wildlife, agriculture, and urba
- SECAmendment: SenesTech Inc. filed SEC Form 8-K: Leadership Update8-K/A - SenesTech, Inc. (0001680378) (Filer)
- PRSenesTech Announces CEO Transition PlanBoard To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.
- SECSenesTech Inc. filed SEC Form 8-K: Leadership Update8-K - SenesTech, Inc. (0001680378) (Filer)
- SECSEC Form SCHEDULE 13G filed by SenesTech Inc.SCHEDULE 13G - SenesTech, Inc. (0001680378) (Subject)
- INSIDERDirector Leach Jacob Steven sold $168 worth of shares (62 units at $2.71), closing all direct ownership in the company (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
- INSIDERDirector Szot Matthew K sold $3 worth of shares (1 units at $2.75), closing all direct ownership in the company (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
- SECSenesTech Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - SenesTech, Inc. (0001680378) (Filer)
- PRSenesTech Expands International Reach with the Addition of the Belize Raptor Center as an Official Distributor of Evolve® Rat Birth ControlSURPRISE, Ariz., Nov. 11, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the pioneer in fertility control for managing animal pest populations, proudly announces the addition of Sarah Mann and the Belize Raptor Center as the newest international distributor of Evolve® Rat Birth Control. Through the leadership of Sarah Mann with the support of the Pesticides Control Board of Belize, Evolve Rat received approval for import and distribution in Belize, a country whose biodiversity is being threatened by the alarming increase of unregulated rodenticides and the severe ecologic
- SECSEC Form 10-Q filed by SenesTech Inc.10-Q - SenesTech, Inc. (0001680378) (Filer)
- SECSenesTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SenesTech, Inc. (0001680378) (Filer)
- PRSenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA77% Revenue Growth in Evolve® Rodent Birth Control™ Products Strong Cash Balance and Progress Toward Profitability SURPRISE, Ariz., Nov. 10, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced its financial results for the third quarter ended September 30, 2025. Q3 2025 Financial Highlights Revenues increased by 43% to $690,000, a record for the Company, from $482,000 in Q3 2024.Evolve® Rodent Birth Control product sales